Fierce Pharma

MAY 20, 2024

Pfizer's Wyeth subsidiary and licensee Puma Biotechnology sued AstraZeneca in 2021 for alleged patent infringement related to AZ's marketing of cancer blockbuster Tagrisso. A Delaware federal jury has ordered AstraZeneca to fork over $107.5

Marketing 324

Marketing 324

MedCity News

FEBRUARY 2, 2023

There were more than 35 million prior authorization requests submitted to MA plans in 2021, and 2 million were denied, according to KFF. Of those denied, just 11% were appealed. However, most of those appeals led to the denial being overturned.

116

116

Fierce Pharma

OCTOBER 8, 2024

Pfizer—which opened a global hub in Tampa, Florida, in 2021—is setting out to bolster emergency services, pool donations and ease medical supply needs as Hurricane Milton touches down this week. Editor's Note: Is your company bracing for Milton or working to provide aid in anticipation of the storm?

Medical 312

Medical 312

MedCity News

APRIL 28, 2023

This marks the third time in about two years that the e-commerce giant has closed one its healthcare businesses — Amazon Care failed last year, and Haven failed in 2021. Amazon recently announced that it is shuttering its Halo division, a line of wearable health and fitness devices.

Healthcare 128

Healthcare Healthcare 128

Fierce Pharma

APRIL 5, 2024

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction than | Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S.

Sales 308

Sales Marketing 308

Fierce Pharma

JANUARY 19, 2024

The lawsuit marks the latest move in Pfizer’s campaign to press countries to honor COVID-19 vaccine contracts inked by the European Commission in May 2021. . | Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania.

321

321

Fierce Pharma

JUNE 16, 2023

After scoring accelerated approval to treat HER2-positive stomach cancer in 2021, the drug has now shown it can stave off tumor progression in patients with PD-L1 positive tumors.

Patients 345

Patients 345

Fierce Pharma

FEBRUARY 21, 2024

Novavax has reached a settlement with Gavi, the Vaccine Alliance ending arbitration tied to a 2021 advance purchase agreement around its prototype COVID-19 vaccine NVX-CoV2373. On the heels of a turbulent 2023 in which Novavax’s very existence was at stake, the beleaguered vaccine maker has new reason to be optimistic about the future.

312

312

Fierce Pharma

FEBRUARY 1, 2024

billion in 2021. Keytruda looks set to take over the top spot from Pfizer and BioNTech’s Comirnaty, which ruled the previous two years, scoring sales of $55.9 billion in 2022 and $55.1

Sales 312

Sales 312

Fierce Pharma

SEPTEMBER 14, 2024

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). | In 2021, the FDA blasted Merck for using premature data to pursue a Keytruda approval in early-stage triple-negative breast cancer.

FDA 246

FDA 246

MedCity News

JANUARY 17, 2023

in 2021 from 11.1% The uninsured rate declined to 10.5% in 2019, according to a recent report from HHS. Some of the largest gains in coverage were among demographic groups that historically have had higher uninsured rates, such as younger adults, Latino individuals, American Indian/Alaska Natives and non-English speaking adults.

Insurance 118

Insurance 118

Fierce Pharma

JANUARY 10, 2024

Despite persistent supply hitches since Wegovy’s launch in 2021, Novo Nordisk has quickly garnered blockbuster sales in the newly untapped obesity market. Despite persistent supply hitches since Wegovy’s launch in 2021, Novo Nordisk has quickly garnered blockbuster sales in the newly untapped obesity market.

Sales 246

Sales Marketing 246

Fierce Pharma

NOVEMBER 28, 2023

Now, months after the country asked for a reprieve from the costs imposed by the 2021 agreement, Pfizer is targeting Poland in court. . | As the pandemic eased earlier this year, officials in Poland became vocal critics of the financial obligations laid down by Pfizer’s large vaccine supply pact with the European Union.

344

344

Fierce Pharma

OCTOBER 17, 2023

After the FDA requested more data in 2021, Ardelyx instead defended its drug's profile through two appeals and an advisory committee meeting. The third time’s the charm for Ardelyx and its chronic kidney disease med Xphozah (tenapanor). Now, the company can celebrate a long-awaited win.

FDA 316

FDA 316

Fierce Pharma

MARCH 13, 2024

The nod comes on top of another for Livmarli to treat Alagille syndrome in 2021, FDA has OKed Mirum’s Livmarli to treat the rare liver disease PFIC.

FDA 264

FDA 264

Fierce Pharma

AUGUST 5, 2024

Bayer’s Kerendia was approved in 2021 to treat patients with chronic kidney disease (CKD) associated with Type 2 diabetes. |

Patients 276

Patients 276

Fierce Pharma

SEPTEMBER 22, 2023

Fast on the heels of winning a European approval to treat chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim's versatile SGLT2 inhibitor Jardiance is expanding its reach in the U.S., | After AstraZeneca's Farxiga won a class-first chronic kidney disease approval back in 2021, Eli Lilly and Boehringer are entering the fray with (..)

FDA 306

FDA 306

Fierce Pharma

APRIL 12, 2024

History is repeating for AstraZeneca CEO Pascal Soriot, who successfully dodged an executive pay revolt at the company’s annual meeting Thursday, echoing a similar situation that played out in 2021 | Out of more than 1.18 million pounds sterling ($23.5 million) for his performance this year.

290

290

Fierce Pharma

JULY 17, 2023

From its initial nod in generalized myasthenia gravis (gMG) in 2021 to a subcutaneous approval this summer—and now, a stellar showing in a second neuromuscular disease—Argenx’s flagship drug Vyvgar | From its initial nod in generalized myasthenia gravis (gMG) in 2021 to a subcutaneous approval this summer—and now, a stellar showing in a second neuromuscular (..)

246

246

Fierce Pharma

MARCH 7, 2024

After posting revenue increases for six straight years, including double-digit growth in 2021 and 2022, Merck KGaA took a hard fall last year, with its global sales

Sales 245

Sales Pharma 245

Fierce Pharma

SEPTEMBER 11, 2023

Supernus is sharing positive results for its nonstimulant ADHD treatment, Qelbree, which was approved for children in 2021. A shortage of attention-deficit/hyperactivity disorder (ADHD) medicines has been ongoing for a year in the U.S. The drug also showed efficacy in adult patients when used over a long period of time.

Medicine 299

Medicine Patients 299

MedCity News

JULY 16, 2023

billion total gross Medicare Part D drug spending in 2021. KFF found that the 10 top-selling Part D drugs represented $47.7 billion of the $215.7 Eliquis, a blood thinner by Bristol Myers Squibb, accounted for the most spending out of these 10 drugs at $12.6 billion.

Prescription 98

Prescription 98

Fierce Pharma

NOVEMBER 6, 2023

While it’s a huge drop in sales from 19 billion euros in 2021 and 17.3 billion) versus its previous estimate of 5 billion euros ($5.4 billion euros in 2022, the company stressed its sound finances on Monday as it presented its third-quarter earnings.

Sales 286

Sales 286

Fierce Pharma

AUGUST 21, 2023

This comes after a bumpy stretch for the medicine since its debut in 2021. . | The FDA will hold an advisory committee meeting to discuss confirmatory trial data for Amgen's Lumakras in KRAS-mutated lung cancer.

FDA 246

FDA Medicine 246

Fierce Pharma

AUGUST 11, 2023

Since Pfizer’s smoking cessation drug Chantix was recalled in 2021, Endo's subsidiary Par Pharmaceuticals has been the only one to market the product.

Pharmaceutical 246

Pharmaceutical Marketing 246

Fierce Pharma

AUGUST 8, 2023

Novo Nordisk has been riding the momentum of weight loss drug Wegovy ever since it stormed onto the market in 2021, creating widespread hype and even some supply shortfalls. | In a large phase 3 trial, Wegovy cut the risk of major adverse cardiovascular events by 20% compared with placebo and standard of care, Novo said Tuesday.

Marketing 246

Marketing 246

Fierce Pharma

JULY 30, 2024

Incyte is gunning for a first-in-class nod for PD-1 inhibitor Zynyz in anal cancer again after being turned away by the FDA in 2021. Incyte is gunning for a first-in-class nod for its PD-1 inhibitor Zynyz in anal cancer again after being turned away by the FDA in 2021. But regulatory uncertainties remain.

FDA 173

FDA 173

World of DTC Marketing

FEBRUARY 11, 2022

Hailing 2021 as “a watershed year” for the company, and predicting more than $50 billion in sales this year for its Covid-19 vaccine and a new therapeutic drug, CEO Albert Bourla declared Tuesday that the opportunities created in this pandemic moment “have fundamentally changed our company forever.”. The Atlantic ).

Government 212

Government Sales Pharmaceutical Pharma 212

World of DTC Marketing

FEBRUARY 1, 2022

According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. According to EY, there were 69 deals worth $128 billion in 2020 and 90 deals worth $108 billion in 2021.

Food and Drug Administration 234

Food and Drug Administration FDA Pharmaceutical Food 234

Fierce Pharma

APRIL 10, 2024

Shipley, who joined the organization in 2021, acted as BIO’s chief advocacy officer—a role in which he oversaw federal and state affairs related to the industry, including issues like government efforts to rein in drug prices.

Government 189

Government 189

World of DTC Marketing

NOVEMBER 19, 2021

In July 2021, Moderna made it clear that it would not name government scientists as co-inventors in a patent application covering a much more significant vaccine component: the mRNA sequence used to produce the vaccine, known as mRNA-1273. As of 9 October 2021, Moderna had provided only 1 million doses to low-income countries.

Government 44

Government Pharma Marketing Sales 44

Fierce Pharma

JULY 20, 2023

billion in 2021. . | The SEC has settled with former Merck Vice President Nirdosh Jagota who allegedly used insider information to make $39,660 on his purchases of stock in Pandion Therapeutics before the biotech was sold to Merck for $1.9

188

188

World of DTC Marketing

DECEMBER 20, 2021

According to the Kaiser Family Foundation (KFF), in 2021, the average cost of employee health insurance premiums for family coverage increased by 4% from the previous year to $22,221. employers during June and July 2021. The average annual premiums for an individual’s plan also increased 4% to $7,739 this year.

Healthcare 209

Healthcare Healthcare Insurance Prescription 209

World of DTC Marketing

JUNE 14, 2022

According to a new report , life expectancy in the United States took another hit in 2021, furthering a dramatic decline from 2020 that was the largest since World War II. years in 2021, a net loss of 2.26 US life expectancy decreased from 78.86 years in 2019 to 76.99 years in 2020 and 76.60 years) and a 0.28-year years) and a 0.28-year

Doctors 176

Doctors Insurance Healthcare Healthcare 176

Fierce Pharma

FEBRUARY 15, 2024

Takeda won FDA approval for Eohilia after a rejection in 2021. Takeda won FDA approval for Eohilia after a rejection in 2021. A group of U.S. lawmakers are seeking federal sanctions against WuXi AppTec and WuXi Biologics. A group of U.S. lawmakers are seeking federal sanctions against WuXi AppTec and WuXi Biologics.

FDA 130

FDA Pharma 130